Ocular Therapeutix News, Ocular Therapeutix Quote, OCUL Quote

Ocular Therapeutix (NQ:OCUL) Delayed: 5.86 --0 (-0%)

Prev. Close

$5.86

Open

$5.86

52 Wk High

$14.50

52 Wk Low

$4.04

Day High

$5.86

Day Low

$5.86

P/E

N/A

EPS

$0.00

Volume

120

Friends, Peers and Foes (?): MOR (more...)

Apr 18, 2024 04:18 PM Ocular Therapeutix (OCUL) Appoints Pravin U. Dugel as CEO
Apr 18, 2024 04:13 PM Form 8-K OCULAR THERAPEUTIX, INC For: Apr 14
Apr 18, 2024 07:01 AM Ocular Therapeutix (OCUL) Reports Positive Topline Phase 1 Data for AXPAXLI
Apr 18, 2024 07:00 AM Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy
Apr 16, 2024 07:03 AM Ocular Therapeutix (OCUL) announces appointment of Nadia K. Waheed, MD, MPH, as Chief Medical Officer
Apr 16, 2024 07:00 AM Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders
Apr 15, 2024 07:02 AM Ocular Therapeutix (OCUL) Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO
Apr 15, 2024 07:00 AM Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO
Apr 9, 2024 07:30 AM Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics
Apr 6, 2024 10:00 AM Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting

Entities mentioned with OCUL